Systemic vasculitis in a patient with rhupus syndrome. 2015

O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
Department of Rheumatology, Gaziantep University, Faculty of Medicine, Gaziantep. drorhanzengin@gmail.com.

Rhupus is a rare syndrome characterized by overlap of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Previous reports mentioned that rhupus patients have prominent RA associated clinical manifestations and only mild organic damage related to SLE. Progressive or life-threatening manifestations are rare in rhupus patients. Our patient diagnosed as rhupus was a young women, presented with multi-organ involvement of systemic vasculitis. Rheumatologists should be aware of possibility that rhupus may be accompanied by progressive or life-threatening conditions such as vasculitis.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D012217 Rheumatoid Factor Autoantibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS. Factor, Rheumatoid
D013577 Syndrome A characteristic symptom complex. Symptom Cluster,Cluster, Symptom,Clusters, Symptom,Symptom Clusters,Syndromes
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
January 2024, Ocular immunology and inflammation,
O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
February 1988, Medicina clinica,
O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
June 2010, Clinical and experimental dermatology,
O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
January 2021, Clinical rheumatology,
O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
July 1988, Archives of internal medicine,
O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
January 2015, The Korean journal of internal medicine,
O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
January 2013, Reumatologia clinica,
O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
January 1989, Recenti progressi in medicina,
O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
December 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
O Zengin, and M E Onder, and M A Sarica, and I H Turkbeyler, and G Kimyon, and Z H Demir, and H Yildiz, and B Kisacik, and A M Onat
January 2023, Southern African journal of infectious diseases,
Copied contents to your clipboard!